These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25924249)

  • 21. First-in-Man trial of a drug-free bioresorbable stent designed to minimize the duration of coronary artery scaffolding.
    Fajadet J; Mennuni MG; Carrié D; Barragan P; Coste P; Vert M; Lafont A
    J Biomater Sci Polym Ed; 2021 Jul; 32(10):1251-1266. PubMed ID: 33792525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of stent strut design in metallic stents and biodegradable scaffolds.
    Foin N; Lee RD; Torii R; Guitierrez-Chico JL; Mattesini A; Nijjer S; Sen S; Petraco R; Davies JE; Di Mario C; Joner M; Virmani R; Wong P
    Int J Cardiol; 2014 Dec; 177(3):800-8. PubMed ID: 25449502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.
    Farooq V; Serruys PW; Heo JH; Gogas BD; Onuma Y; Perkins LE; Diletti R; Radu MD; Räber L; Bourantas CV; Zhang Y; van Remortel E; Pawar R; Rapoza RJ; Powers JC; van Beusekom HM; Garcìa-Garcìa HM; Virmani R
    JACC Cardiovasc Interv; 2013 May; 6(5):523-32. PubMed ID: 23702016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of bioresorbable stents in the superficial femoral artery.
    Vermassen F; Bouckenooghe I; Moreels N; Goverde P; Schroe H
    J Cardiovasc Surg (Torino); 2013 Apr; 54(2):225-34. PubMed ID: 23558658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term patient benefit with biodegradable polymer biolimus eluting stent.
    Corti R
    Minerva Cardioangiol; 2012 Dec; 60(6):629-36. PubMed ID: 23147439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioresorbable scaffolds for complex coronary interventions.
    Lesiak M; Zawada-Iwańczyk S; Łanocha M; Klotzka A; Lesiak M
    Minerva Cardioangiol; 2018 Aug; 66(4):477-488. PubMed ID: 29546748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable scaffolds for the SFA: new developments.
    Werner M
    J Cardiovasc Surg (Torino); 2014 Aug; 55(4):455-9. PubMed ID: 24866776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: the next revolution in coronary intervention?
    Patel N; Banning AP
    Heart; 2013 Sep; 99(17):1236-43. PubMed ID: 23474621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel.
    Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654
    [No Abstract]   [Full Text] [Related]  

  • 32. Absorbable stent: focus on clinical applications and benefits.
    Gonzalo N; Macaya C
    Vasc Health Risk Manag; 2012; 8():125-32. PubMed ID: 22399857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioresorbable scaffolding after drug-coated balloons: a new chapter of the "leave nothing behind" saga.
    Cortese B; Sebik R; Seregni R; Silva PL
    Int J Cardiol; 2014 May; 173(3):e67-9. PubMed ID: 24704408
    [No Abstract]   [Full Text] [Related]  

  • 34. Bioresorbable vascular scaffolds: Biodegradation, drug delivery and vascular remodeling.
    Tesfamariam B
    Pharmacol Res; 2016 May; 107():163-171. PubMed ID: 27001225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation.
    Iaccarino D; Politi L; Rossi R; Sgura F; Monopoli D; Modena MG; Sangiorgi GM
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):536-43. PubMed ID: 20090547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel drug-eluting stents for coronary revascularization.
    Gogas BD; McDaniel M; Samady H; King SB
    Trends Cardiovasc Med; 2014 Oct; 24(7):305-13. PubMed ID: 25240980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expectation for new-generation drug eluting stents].
    Saito S
    Nihon Rinsho; 2011 Feb; 69(2):237-9. PubMed ID: 21387669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.